All Studies

Glabridin plays dual action to intensify anti-metastatic potential of paclitaxel via impeding CYP2C8 in liver and CYP2J2/EETs in tumor of an orthotopic mouse model of breast cancer.

Glabridin, a compound found in Glycyrrhiza glabra, has shown potential in the treatment of Triple-negative breast cancer (TNBC). In a mouse model, glabridin enhanced the effectiveness of the front-line therapy, paclitaxel, by reducing tumor burden and inhibiting the formation of lung nodules. It also reversed the traits of hostile cancer cells and promoted apoptosis in tumor tissue. Furthermore, glabridin improved the pharmacokinetics of paclitaxel by slowing down its metabolism in the liver. With its dual role in enhancing anti-metastatic activity and limiting tumorigenesis, glabridin shows promise as a potential neoadjuvant therapy for paclitaxel chemoresistance and cancer recurrence. Further research is needed to fully explore its potential.

Jamwal A et al (2023).
Chem Biol Interact.
PubMed:
37419298

Aqueous extract of pummelo pulp (Citrus maxima) improves the biochemical profile and reduces the inflammation process in Wistar rats with non-alcoholic fatty liver disease.

Tejada Nunes V et al (2023).
Food Chem Toxicol.
PubMed:
37419271

Caffeoylquinic acids isolated from Lonicera japonica Thunb. as TAK1 inhibitors protects against LPS plus IFN-γ-stimulated inflammation by interacting with KEAP1-regulated NRF2 activation.

Ge L et al (2023).
Biomed Pharmacother.
PubMed:
37418981